Drug Repurposing Platforms Have Become a Drug Discovery Shortcut That Big Pharma Cannot Ignore

The Drug That Already Passed Safety Testing for Something Else

Drug development from the initial identification of a therapeutic target through the completion of Phase 3 clinical trials to regulatory approval requires on average ten to fifteen years and approximately $2.5 to $3 billion in total investment, with the majority of the cost and time concentrated in the later-stage clinical development whose failure rate of over ninety percent from Phase 1 entry to approval creates the economics of pharmaceutical innovation whose blockbuster model depends on the few successful drugs generating sufficient revenue to subsidise the far larger number of failed development programmes. The fundamental bottleneck is not the science of identifying molecules that interact with therapeutic targets but the clinical safety and toxicology evidence whose generation in human subjects requires the Phase 1 and Phase 2 trials whose duration and cost are independent of whether the molecule is a novel chemical entity or a molecule whose human safety profile has already been established through approved use in a different indication. Drug repurposing exploits this asymmetry by identifying new therapeutic applications for compounds whose human safety, pharmacokinetic, formulation, and manufacturing characteristics are already known from their existing approved use, allowing the clinical development programme for the new indication to begin at Phase 2 efficacy assessment rather than Phase 1 safety escalation, reducing the time from target to approval from fifteen years to three to seven years and the investment from $2.5 billion to $300 to $700 million in cases where the existing clinical data package eliminates the largest categories of development risk.

The drug repurposing market, encompassing the AI and computational drug repurposing platform companies whose technology generates the repurposing hypotheses, the contract research and clinical development organisations that execute the clinical programmes, and the pharmaceutical companies whose pipeline includes repurposed compounds, is valued at approximately $32 billion in 2026 when the total clinical-stage pipeline value of repurposed drug candidates is included, and at approximately $5.4 billion for the technology platform and services segment. The drug repurposing technology market is growing at approximately fifteen percent annually as AI and machine learning platforms that analyse the multi-omic data, electronic health records, clinical trial results, and molecular interaction networks that define drug-disease relationships create the systematic hypothesis generation that manual literature review and serendipitous clinical observation could not previously achieve at scale.

BenevolentAI and the Target Identification Platform

BenevolentAI, the UK-listed AI drug discovery company, has built its drug repurposing commercial position around its knowledge graph platform whose integration of biomedical literature, clinical trial data, genomic databases, and molecular interaction networks creates the connected representation of biological knowledge that the company's machine learning algorithms query to identify non-obvious connections between approved drugs, disease mechanisms, and patient populations that human researchers are unlikely to discover through conventional literature review. Its identification of baricitinib, the JAK inhibitor approved for rheumatoid arthritis, as a potential treatment for COVID-19 through the analysis of the cytokine signalling pathways whose dysregulation in severe COVID-19 shared mechanistic overlap with the inflammatory pathways that baricitinib inhibits, and the subsequent randomised controlled trial evidence that validated baricitinib's efficacy in hospitalised COVID-19 patients, demonstrated the commercial value of AI-driven repurposing hypothesis generation whose speed of identification from published data to clinical validation exceeded what conventional drug discovery timelines could achieve for a novel therapeutic agent. The baricitinib COVID-19 repurposing represents the highest-profile validated repurposing prediction from an AI platform and has established BenevolentAI's platform credibility with the pharmaceutical partnership community.

Exscientia, the UK AI-driven drug design company, applies its generative AI drug design platform to both de novo drug design and to the repurposing and optimisation of known compounds whose structural modifications create improved potency, selectivity, or pharmacokinetic profiles for new indications. Its clinical-stage pipeline that includes AI-designed compounds that have entered Phase 1 trials, including the world's first AI-designed drug molecule to enter human clinical trials, creates the validation evidence that its pharmaceutical partnership and licensing business model requires to demonstrate that AI-designed compounds can achieve the clinical performance that conventionally discovered drugs attain. Atomwise, the US AI drug discovery company whose convolutional neural network structural biology prediction platform screens the approved drug library against disease-relevant protein targets to identify off-target interactions that could be repurposed as therapeutic activity in new indications, has built a partnership portfolio with major academic medical centres and pharmaceutical companies whose repurposing project collaborations create the clinical pipeline whose eventual approvals will quantify the commercial returns from AI-driven repurposing at scale.

The COVID-19 Legacy and Systematic Repurposing Infrastructure

The COVID-19 pandemic accelerated drug repurposing platform adoption by demonstrating that systematic computational screening of the approved drug library could generate clinically actionable repurposing hypotheses faster than any alternative drug discovery approach, and that the clinical trial infrastructure whose rapid mobilisation for COVID-19 trials could validate repurposing hypotheses at a speed that the pre-pandemic clinical research system could not have achieved. The RECOVERY trial in the United Kingdom, which tested multiple repurposed drugs in hospitalised COVID-19 patients and identified dexamethasone's mortality benefit and baricitinib's clinical improvement benefit through the adaptive trial platform whose rapid enrolment and interim analysis enabled the earliest possible evidence generation, created the institutional learning about repurposing trial design whose methodology is being applied to the repurposing programmes for antimicrobial resistance, rare diseases, and oncology that the post-pandemic drug development community is pursuing with renewed urgency.

Top 10 Companies in Drug Repurposing Platforms and AI Drug Discovery Globally

1. BenevolentAI: UK AI drug discovery company with knowledge graph platform and the baricitinib COVID-19 repurposing validation; its biomedical knowledge graph and its AstraZeneca and Pfizer partnerships create the AI repurposing platform whose published repurposing prediction validation has established the commercial credibility that pharmaceutical partnership contracts require.
2. Exscientia: UK AI drug design company with generative AI for drug optimisation and the world's first AI-designed molecule to enter Phase 1 trials; its compound optimisation platform and its Bristol Myers Squibb and Sanofi partnership create the AI drug design company whose clinical pipeline demonstrates AI's ability to design molecules that reach human trials.
3. Atomwise: US AI drug discovery company with convolutional neural network protein-ligand binding prediction for repurposing and new compound discovery; its academic and pharmaceutical partnership network and its approved drug library screening create the AI repurposing platform whose structural biology prediction capabilities serve both repurposing and novel compound discovery.
4. Insilico Medicine: Hong Kong-US AI drug discovery company with generative AI for both target discovery and molecule generation; its first AI-discovered and AI-designed drug molecule advancing through Phase 2 trials for IPF and its Biology42 platform create the AI drug discovery company whose pipeline validates AI's ability to identify novel targets and generate clinical candidate molecules.
5. Recursion Pharmaceuticals: US AI-driven drug discovery company with high-throughput phenotypic screening and machine learning for repurposing and novel indication discovery; its NVIDIA partnership and its phenomics data platform create the drug discovery company whose biological image-based screening approach generates repurposing hypotheses from cellular phenotypic data rather than structural biology or literature knowledge graphs.
6. Vividion Therapeutics (Bayer): US chemoproteomic drug discovery company acquired by Bayer with target discovery capabilities for repurposing and novel drug design; its chemoproteomics platform that identifies druggable protein sites and its Bayer pharmaceutical development integration create the discovery-to-development pipeline for both novel and repurposed compound programmes.
7. Schrödinger: US computational chemistry company with physics-based drug design software for repurposing and novel drug optimisation; its Free Energy Perturbation platform and its pharmaceutical licensing model create the computational chemistry software company whose structural biology prediction tools are used by pharmaceutical companies' internal computational chemistry teams for repurposing candidate evaluation.
8. Healx: UK AI drug repurposing company focused on rare diseases; its Healnet AI platform identifying repurposing opportunities for the rare disease patient populations whose small size makes de novo drug development economically impractical creates the repurposing platform for the rare disease application where the development cost advantage of repurposing over novel drug development is most commercially compelling.
9. Numerate: US AI drug design and repurposing company with machine learning for molecular property prediction and repurposing hypothesis generation; its pharmaceutical partnership model and its machine learning property prediction create the computational drug design company serving the pharmaceutical industry's internal drug discovery teams whose AI augmentation with external platform partnerships is the commercial model that AI drug discovery companies are building around.
10. PharmAI: German AI drug repurposing company with patent and scientific literature mining for repurposing opportunity identification; its natural language processing of the biomedical patent and literature databases and its European pharmaceutical market focus create the repurposing intelligence company whose text mining approach complements the structural biology and knowledge graph approaches of the US and UK repurposing platform companies.